Photodynamic therapy of experimental choroidal melanoma using lipoprotein- delivered benzoporphyrin

U. Schmidt-Erfurth, W. Bauman, E. Gragoudas, Thomas J Flotte, N. A. Michaud, R. Birngruber, T. Hasan

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Background: Benzoporphyrin derivative monoacid (BPD) is a new photosensitizer currently undergoing clinical trial for cutaneous malignancies. Compared with the clinically most frequently used sensitizer, Photofrin, BPD may offer higher tumor phototoxicity, better tissue penetration, and absence of significant skin sensitization. Low-density lipoprotein (LDL) carriers heighten efficiency and selectivity of BPD because neovascular and tumor cells express an increased number of LDL receptors. Hence, in addition to the vaso-occlusive effects similar to most other photosensitizers, LDL-BPD also has been shown to cause direct tumor cell damage. Methods: Benzoporphyrin derivative monoacid was complexed with human LDL and used in photodynamic treatment of choroidal melanomas experimentally induced in eight albino rabbits. Five rabbits served as controls. Three hours after intravenous injection of 2 mg/kg body weight of LDL-BPD, eight tumors were irradiated at 692 nm and 100 J/cm2 via an argon-pumped dye laser coupled into a slit lamp. Results: Angiography and histologic findings showed immediate photothrombosis after disintegration of endothelial membranes. After complete necrosis of tumor cells within 24 hours, a small fibrotic scar slowly developed. No tumor regrowth was noted up to 6 weeks when animals were killed. Conclusion: These data suggest that photodynamic treatment with LDL- BPD may be a promising modality for multiple clinical applications, including tumors and neovascularizations II.

Original languageEnglish (US)
Pages (from-to)89-99
Number of pages11
JournalOphthalmology
Volume101
Issue number1
StatePublished - 1994
Externally publishedYes

Fingerprint

Experimental Melanomas
Photochemotherapy
Lipoproteins
LDL Lipoproteins
Neoplasms
Photosensitizing Agents
Dihematoporphyrin Ether
Rabbits
Phototoxic Dermatitis
Dye Lasers
Skin
Argon
LDL Receptors
Intravenous Injections
Cicatrix
Melanoma
Angiography
Necrosis
Body Weight
Clinical Trials

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Schmidt-Erfurth, U., Bauman, W., Gragoudas, E., Flotte, T. J., Michaud, N. A., Birngruber, R., & Hasan, T. (1994). Photodynamic therapy of experimental choroidal melanoma using lipoprotein- delivered benzoporphyrin. Ophthalmology, 101(1), 89-99.

Photodynamic therapy of experimental choroidal melanoma using lipoprotein- delivered benzoporphyrin. / Schmidt-Erfurth, U.; Bauman, W.; Gragoudas, E.; Flotte, Thomas J; Michaud, N. A.; Birngruber, R.; Hasan, T.

In: Ophthalmology, Vol. 101, No. 1, 1994, p. 89-99.

Research output: Contribution to journalArticle

Schmidt-Erfurth, U, Bauman, W, Gragoudas, E, Flotte, TJ, Michaud, NA, Birngruber, R & Hasan, T 1994, 'Photodynamic therapy of experimental choroidal melanoma using lipoprotein- delivered benzoporphyrin', Ophthalmology, vol. 101, no. 1, pp. 89-99.
Schmidt-Erfurth U, Bauman W, Gragoudas E, Flotte TJ, Michaud NA, Birngruber R et al. Photodynamic therapy of experimental choroidal melanoma using lipoprotein- delivered benzoporphyrin. Ophthalmology. 1994;101(1):89-99.
Schmidt-Erfurth, U. ; Bauman, W. ; Gragoudas, E. ; Flotte, Thomas J ; Michaud, N. A. ; Birngruber, R. ; Hasan, T. / Photodynamic therapy of experimental choroidal melanoma using lipoprotein- delivered benzoporphyrin. In: Ophthalmology. 1994 ; Vol. 101, No. 1. pp. 89-99.
@article{e70fec50a068483dbccf4a90d85a17e9,
title = "Photodynamic therapy of experimental choroidal melanoma using lipoprotein- delivered benzoporphyrin",
abstract = "Background: Benzoporphyrin derivative monoacid (BPD) is a new photosensitizer currently undergoing clinical trial for cutaneous malignancies. Compared with the clinically most frequently used sensitizer, Photofrin, BPD may offer higher tumor phototoxicity, better tissue penetration, and absence of significant skin sensitization. Low-density lipoprotein (LDL) carriers heighten efficiency and selectivity of BPD because neovascular and tumor cells express an increased number of LDL receptors. Hence, in addition to the vaso-occlusive effects similar to most other photosensitizers, LDL-BPD also has been shown to cause direct tumor cell damage. Methods: Benzoporphyrin derivative monoacid was complexed with human LDL and used in photodynamic treatment of choroidal melanomas experimentally induced in eight albino rabbits. Five rabbits served as controls. Three hours after intravenous injection of 2 mg/kg body weight of LDL-BPD, eight tumors were irradiated at 692 nm and 100 J/cm2 via an argon-pumped dye laser coupled into a slit lamp. Results: Angiography and histologic findings showed immediate photothrombosis after disintegration of endothelial membranes. After complete necrosis of tumor cells within 24 hours, a small fibrotic scar slowly developed. No tumor regrowth was noted up to 6 weeks when animals were killed. Conclusion: These data suggest that photodynamic treatment with LDL- BPD may be a promising modality for multiple clinical applications, including tumors and neovascularizations II.",
author = "U. Schmidt-Erfurth and W. Bauman and E. Gragoudas and Flotte, {Thomas J} and Michaud, {N. A.} and R. Birngruber and T. Hasan",
year = "1994",
language = "English (US)",
volume = "101",
pages = "89--99",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Photodynamic therapy of experimental choroidal melanoma using lipoprotein- delivered benzoporphyrin

AU - Schmidt-Erfurth, U.

AU - Bauman, W.

AU - Gragoudas, E.

AU - Flotte, Thomas J

AU - Michaud, N. A.

AU - Birngruber, R.

AU - Hasan, T.

PY - 1994

Y1 - 1994

N2 - Background: Benzoporphyrin derivative monoacid (BPD) is a new photosensitizer currently undergoing clinical trial for cutaneous malignancies. Compared with the clinically most frequently used sensitizer, Photofrin, BPD may offer higher tumor phototoxicity, better tissue penetration, and absence of significant skin sensitization. Low-density lipoprotein (LDL) carriers heighten efficiency and selectivity of BPD because neovascular and tumor cells express an increased number of LDL receptors. Hence, in addition to the vaso-occlusive effects similar to most other photosensitizers, LDL-BPD also has been shown to cause direct tumor cell damage. Methods: Benzoporphyrin derivative monoacid was complexed with human LDL and used in photodynamic treatment of choroidal melanomas experimentally induced in eight albino rabbits. Five rabbits served as controls. Three hours after intravenous injection of 2 mg/kg body weight of LDL-BPD, eight tumors were irradiated at 692 nm and 100 J/cm2 via an argon-pumped dye laser coupled into a slit lamp. Results: Angiography and histologic findings showed immediate photothrombosis after disintegration of endothelial membranes. After complete necrosis of tumor cells within 24 hours, a small fibrotic scar slowly developed. No tumor regrowth was noted up to 6 weeks when animals were killed. Conclusion: These data suggest that photodynamic treatment with LDL- BPD may be a promising modality for multiple clinical applications, including tumors and neovascularizations II.

AB - Background: Benzoporphyrin derivative monoacid (BPD) is a new photosensitizer currently undergoing clinical trial for cutaneous malignancies. Compared with the clinically most frequently used sensitizer, Photofrin, BPD may offer higher tumor phototoxicity, better tissue penetration, and absence of significant skin sensitization. Low-density lipoprotein (LDL) carriers heighten efficiency and selectivity of BPD because neovascular and tumor cells express an increased number of LDL receptors. Hence, in addition to the vaso-occlusive effects similar to most other photosensitizers, LDL-BPD also has been shown to cause direct tumor cell damage. Methods: Benzoporphyrin derivative monoacid was complexed with human LDL and used in photodynamic treatment of choroidal melanomas experimentally induced in eight albino rabbits. Five rabbits served as controls. Three hours after intravenous injection of 2 mg/kg body weight of LDL-BPD, eight tumors were irradiated at 692 nm and 100 J/cm2 via an argon-pumped dye laser coupled into a slit lamp. Results: Angiography and histologic findings showed immediate photothrombosis after disintegration of endothelial membranes. After complete necrosis of tumor cells within 24 hours, a small fibrotic scar slowly developed. No tumor regrowth was noted up to 6 weeks when animals were killed. Conclusion: These data suggest that photodynamic treatment with LDL- BPD may be a promising modality for multiple clinical applications, including tumors and neovascularizations II.

UR - http://www.scopus.com/inward/record.url?scp=0028010029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028010029&partnerID=8YFLogxK

M3 - Article

C2 - 8302569

AN - SCOPUS:0028010029

VL - 101

SP - 89

EP - 99

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 1

ER -